I am aligned with JBN on this. Whilst there is no certainty of course, it's highly unlikely there won't be a strong demand for the product given all the setbacks of current treatments and uniqueness of Spontan, and also because of what has been communicated by the company about being inundated with requests for the product. I don't see any reason at this time to not accept the veracity of that communication.
LTP Price at posting:
73.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)